Keith Abe
About Keith Abe
Keith Abe serves as the Director of Translational In Vivo Pharmacology at Mammoth Biosciences in Brisbane, California, a position he has held since 2021. He has extensive experience in the pharmaceutical industry, having worked in various roles at companies such as BioMarin Pharmaceutical Inc., Bayer, and CRISPR Therapeutics.
Work at Mammoth Biosciences
Keith Abe serves as the Director of Translational In Vivo Pharmacology at Mammoth Biosciences, a position he has held since 2021. His role involves overseeing pharmacological studies that translate preclinical findings into potential therapeutic applications. Located in Brisbane, California, Mammoth Biosciences focuses on developing CRISPR-based diagnostics and therapeutics. Abe's expertise contributes to the company's mission of advancing innovative solutions in the field of biotechnology.
Previous Experience in Pharmaceutical Industry
Before joining Mammoth Biosciences, Keith Abe worked at BioMarin Pharmaceutical Inc. as an Associate Director from 2020 to 2021. His career includes significant roles at several companies, such as Bayer, where he served as a Staff Scientist from 2012 to 2016, and Casebia Therapeutics, where he was a Senior Scientist from 2017 to 2019. He also held positions at CRISPR Therapeutics and Portola Pharmaceuticals, further establishing his expertise in translational pharmacology.
Educational Background
Keith Abe studied at the University of California, Davis, from 1988 to 1993, where he completed his undergraduate education. His academic background laid the foundation for his extensive career in the pharmaceutical and biotechnology sectors, equipping him with the knowledge and skills necessary for his roles in translational pharmacology.
Career Development Timeline
Keith Abe's career spans several key positions in the biotechnology and pharmaceutical industries. He began as a Research Assistant II and Lab Manager at Stanford University School of Medicine from 1994 to 1998. He then progressed through various roles, including Scientist II at Pacific BioLabs in 2012, Senior Scientist I at Portola Pharmaceuticals from 2005 to 2011, and Senior Scientist at both Casebia Therapeutics and CRISPR Therapeutics. This timeline reflects his growth and expertise in the field.